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ABSTRACT
Pooled urine samples from patients receiving 100- 200 mg of naltrexone per day orally were
extracted; the basic (alkaloid) compounds derived were isolated by preparative thin-layer chromatography. The major metabolite of naltrexone was found to be an epimer of N-cyclopropylmethyl- 14 -hydroxy-7.8-dihydronormorphine wherein the 6-keto group of naltrexone had been
reduced to yield the 6,6-hydroxy epimer (an isomorphine). This conclusion was based on infra red. mass. and nuclear magnetic resonance spectra studies. Furthermore. the reduction product formed in vitro in a soluble chicken liver enzyme system from naltrexone and an in vivo
metabolite of naloxone derived from the chicken were found to have the more commonly ex pected 6a-hydroxy orientation.

Naltrexone (EN 1639) is a narcotic antagonist
which possesses a long duration of action and is
currently under evaluation for the prevention of
opiate dependence. Because of our interest in the
comparative metabolism of a related narcotic
antagonist, naloxone ( 1- 3), we undertook the
present study. The chemical difference between
these compounds is that the alkyl moiety on the
nitrogen atom is an allyl group for naloxone ( la)
and a cyclopropylmethyl group for naltrexone
(lb). The major metabolite of naloxone in man is
naloxone-3-glucuronide (2); also a small amount of
a 6-keto reduced product, N-allyl-14-hydroxy-7 ,8dihydronormorphine-3-glucuronide, is formed (4).
In the rabbit, a similar predominance of naloxone3-glucuronide is seen (I, 4 ); however, in the
chicken, the dihydronormorphine glucuronide derivative is by far the predominant metabolite.
Based on these past studies with naloxone we were
surprised to find in the present study that in man a
major metabolite of naltrexone was the product of
reduction of the 6-keto group; furthermore, it was
the 6~-hydroxy (2a) rather than the 6a-epimer
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(2b ). This paper deals with the isolation and
identification of this reduction product and gives
further justification by way of nuclear magnetic
resonance (NMR) spectral data for the 6,6-0H
configuration initially assigned to the metabolite
by Cone et a/. (5).
Materials and Methods
Source of Materials. Five gallons of pooled urine from
patients receiving 100- 200 mg of naltrexone orally per
day were sent to the laboratory in Milwaukee (J.M.F.)
through the cooperation of Dr. Richard B. Resnick of the
Department of Psychiatry, New York Medical College.
The urine was preserved for shipment with a layer of
toluene. Naltrexone hydrochloride (EN 1639A) and
naloxone hydrochloride were generously provided by Dr.
Harold Blumberg, Endo Laboratories, Garden City,
N.Y., and an authentic sample of EN 2260A, N-cyclopropylmethyl-14-hydroxy-7 ,8-dihydronormorphine hydrochloride was a gift from Dr. Everette L. May,
National Institute of Arthritis, Metabolism, and Digestive Diseases, Bethesda, Md. Reduced naloxone identical
with EN 2265, N-allyl-14-hydroxy-7 ,8-dihydronorrnorphine, was made by us (N.C., C.E.I.) by reducing
naloxone with NaBH~. The suffix A (e.g., EN 2260A)
refers to the hydrochloride salt. When A is omitted, the
free base is meant.
Thin-Layer Chromatography. Major analytical techniques have been described in previous publications (1 ,
6). The main system for separation of relatively less polar
unconjugated metabolites and naltrexone itself consisted
of a solvent system of benzene/hexane/diethylamine
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(25: 10:2, v jv) (BHD) used with Gelman Silica Gel SG
sheets. In certain experiments, solvent system A (ethyl
acetate/ hexane/ethanol /a mmonia, 60:25:14:1) was used
on Analtech silica gel plates. lodoplatinate reagent and
Dragendorffs reagent were used to visualize alkaloidal
bases, and concentrated H 2S0 4 spray followed by charring on a hotplate was resorted to for detecting organic
material.
Isolation of Metabolites from Human Urine. In initial
attempts to isolate metabolites we used the Amberlite
XAD-2 resin column procedure as dictated by experience
in isolating conjugated metabolites of naloxone (I - 3),
nalorphine (7), morphine (8), and dihydromorphinone
(9). It soon became evident, however, that most of the
naltrexone metabolites were in unconjugated form and
could be purified by solvent extractions as follows. After
filtration by mixing with about 0.25 volume of diatomaceous earth, 1200 ml of urine in several 1-liter bottles
were made alkaline by adding NaOH pellets until basic
to litmus paper. Several grams of NaHC0 3 were then
added to each bottle to make the pH about 8.5 . This
urine was extracted with a total volume of 1000 ml of
ethyl acetate. The ethyl acetate phase was decanted and
filtered through diatomaceous earth (a procedure which
breaks emulsions). The ethyl acetate phase was evaporated under vacuum in a rotating flask apparatus to yield
a moderately brown-colored residue. This material was
dissolved in 150 ml of ethyl acetate and the mixture was
extracted with 40 ml of 0.5 N HCL The aqueous acid
phase was separated and evaporated to dryness under
reduced pressure. The residue dissolved in about 1 ml of
methanol was streaked several times with a Cordis 50-,ul
applicator, on two 20 x 20-cm Gelman Silica Gel SG
thin-layer chromatography (TLC) sheets. After developing (BHD 1 solvent) and drying, a thin vertical strip ( 1/2
in.) of the chromatogram was cut and sprayed with
iodoplatinate reagent to locate alkaloids. On the basis of
this localization, the sheets were cut horizontally into
four sections, covering the following approximate range
of RF values: 1.0 0.9, 0.9 0.7, 0.7 0.2, and 0.2- 0. Each
of the horizontal strips was eluted with liberal quantities
of methanol (about 10- 30 ml, the larger volume for the
larger strips) delivered from a wash bottle. The correThe abbreviations used are: BH D. benzene/ hexane/
diethylamine; NMR. nuclear magnetic resonance; TLC.
1

thin-layer chromatography: IR. infrared.

sponding fractions from the two chromatograms were
pooled. On analytical TLC of each of the above four
fractions, the RF = 0. 7 0.2 material gave a single spot of
RF = 0.3. It appeared that the broad band was obtained
on the preparative plates because of overloading. No
other organic material was perceptible in this major
fraction. This material was used for mass and infrared
spectral analysis. As a secondary study, the materials
recovered in the streaked bands of RF = 1.0- 0.9 and
0.9 0.7, both of which contained mixtures of alkaloids as
well as other contaminants (seen as ultrav iolet fluorescent spots), were pooled and streaked on plates as before.
The plates were developed, cut into strips, and eluted
with methanol. This procedure gave four separated
alkaloids with RF of 1.0, 0.8, 0.7, and 0.5 in the BHD
solvent system.
For purposes of NMR determination, an additional
series of purification steps was carried out on the major
RF 0.3 fraction. The residue dissolved in HCl was
extracted with n-butyl chloride. The free base was
precipitated with ammonium carbonate (pH = 9) from
the aqueous layer. This precipitate was extracted into
chloroform and subjected to preparative TLC on silica
gel plates (Analtech) using solvent system A. This
procedure gave a compound which showed RF = 0.49
(solvent system A). The material was extracted into
chloroform and treated with Norit, filtered, and lyophilized to give a very small quantity of the free base
(naltrexone metabolite). Multiple purifications of this
material were carried out by dissolving in a minimum
volume of chloroform and adding hexane and allowing
the mixture to stand. The solid residues were washed and
centrifuged to remove supernatant mother liquor. This
procedure yie lded a sample of approximately 0.5 mg of
the free base, the NMR spectrum of which appeared to
reveal a rel atively pure compound, except for one
absorption in the aliphatic region which was not readily
accountable. For consistency, this naltrexone metabolite
will be designated as the RF = 0.3 compound (referring
back to the RF obtained in the BHD solvent system) or
human metabolite.
In Vitro Enzyme System. An enzyme system from the
soluble fraction of chicken liver homogenates (I 0) was
used to reduce naltrexone in vitro. The incubation
mixture consisted of the following: 31.6 mg of purified
enzyme protein mixture, 290 .umol of glucose 6-phos-
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phate; 0.5 J.Lmol of NADP+; 5 units of glucose 6-phosphate dehydrogenase; 0.8 ml of 0.05 M KH 2 PO./N aOH
buffer, pH 7 .4; and 40 J.Lmol of naltrexone, all in a final
volume of 3 ml. The purified protein mixture was
prepared by making a 1OO,OOOg supernatant fraction of a
chicken liver homogenate, preparing a fraction which
precipitated at 45- 65% saturation with ammonium sulfate, and purifying this fraction further by DEAE-cellulose column chromatography. After incubation for 180
min, the mixture was adjusted to pH 8.5 with strong
base and addition of NaHC0 3 , and extracted with ethyl
acetate. The ethyl acetate phase was reduced in volume
and processed by preparative TLC as described above.
This metabolite (with RF = 0.3 in BHD) was easily
crystallized as the HCl salt and was called chicken metabolite of naltrexone.
An in vivo metabolite of naloxone isolated from
chicken urine was included in this study ( 1). The
N -allyl-14-hydroxy-7 ,8-dihydronormorphine-3-glucuronide was hydrolyzed in hydrochloric acid and the liberated free base form was isolated by extraction as above.
Further Analytical Procedures. For infrared (l R) analysis, methanol solutions of the materials were concentrated on to KBr wicks (Wick-Stick, Harshaw Chemicals, Cleveland, Ohio). The tips of the wicks were made
into micro pellets. I R spectra were obtained with a
Perkin-Elmer model 457 infrared spectrophotometer.
Proton NMR spectra were run on a Varian XL-100
spectrometer in 5-mm sample tubes in a V-4405A probe.
Fourier transform spectra were run with a Transform
Technology TT-I 00 instrument using an NM R-800
computer and a TT-1010 Apulse transmitter. Ninetydegree tilt times for protons average 11 J.LSec. The Fourier
transform spectra were plotted on the XL-100 recorder
which was interfaced to the TT-100 instrument. The
spectra of the free bases were obtained in CDC13 •
Electron ionization mass spectra reported here were
obtained on a Dupont 21-492 mass spectrometer by The
Rockefeller University Mass Spectrometry Service Laboratory, New York, N.Y.

Results and Discussion
The isolated materials with RF = 0.3, as discussed in the previous section, chromatographed
like authentic EN 2260. The fR curves (not
reproduced here) lacked absorption in the 5.8-,u.
region as did authentic EN 2260A. This result is in
accord with Cone ( 11). The conclusion that the
6-keto group of naltrexone was reduced in both the
human and chicken metabolites was thus in keeping with the metabolic reduction observed elsewhere (I, 9).
The mass spectral data given in table I helped
establish the molecular weight of the human and
chicken metabolites to be 343. A good relative
order of intensities is seen between authentic EN
2260A and the RF = 0.3 metabolites. All 10 peaks
of the known were present in the unknowns, so that
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the EN 2260A skeleton appeared to be present in
the unknowns. Thus, the compounds have a chemi~
cal formula of C2oH2 5 NO •. The data so far (IR
and mass spectral) pointed clearly to a reduction of
naltrexone to the alcohol.
In Table 1, the mass spectral data for the RF =
0.8 fraction indicated that unchanged naltrexone
was present in the human urine sample. This
fraction also appeared to be contaminated with
caffeine because of a strong peak at m/ e 194. The
other fractions (Rr 1, 0. 7, and 0.5) did not yield
mass spectral data which could be interpreted to
indicate N-dealkylated products of either naltrexone or EN 2260 and were not examined further.
In order to arrive at the epimeric nature of the
alcohol formed (human and chicken metabolites),
we studied the proton NMR of these compounds.
This portion of the study was initiated when one of
u~ (N.C.) chemically reduced naloxone to obtain a
compound which was found to be identical with
EN 2265 as a result of the NMR study. This study
gave rise to results which confirmed the epimeric
nature of 6a-OH and 6/3-0H compounds of various morphine derivatives (having 14-0H substitution). As seen in table 2, the chemical shifts of the
C-5 and C-6 protons of the morphinan skeleton of
various 14-0H derivatives are listed. We found
that the 14-0H group did not seem to appreciably
influence the chemical shift of the protons at C-6 in
comparison with compounds that lacked the
14-0H group (12). Furthermore, in table 2, the
chemical shifts of selected compounds of both the
14-hydroxy-7 ,8-dihydromorphine type and the isomorphine configuration (6/3-0H) are given with
respect to the 5/3 and 6/3 or 6a proton absorbances.
It is seen in compounds having the 6a-OH group
such as morphine, EN 2260, and EN 2265 that the
6{3 proton appears at somewhat lower fields than if
it were a proton with 6a orientation (as in 6/3-0H
compounds). Comparison of the chemical shifts of
the 5/3 and 6/3 protons of chemically reduced
naltrexone and naloxone (EN 2260 and EN 2265,
respectively) shows these compounds to be of
similar structure (6a-OH orientation). EN 2260
exhibits a doublet centered at o4.67 (J = 4.5 Hz)
due to the 5{j proton and a multiplet between
4.38 - 4.16 due to the 6/3 proton. For EN 2265 the
corresponding values are at o 4.67 (doublet, J =
4.5 Hz) and o 4.40- 4.18 (multiplet), respectively .
These chemical shift values are in good agreement
with the values for the corresponding 5/3 and 6/3
protons of dihydrocodeine, which has the 6a-OH
orientation although it lacks the 14-0H group
(II). There is again good agreement between the

o
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TABLE I

Electron ionization mass spectra of naltrexone (EN 1639A ),
N-cyc/opropylmethyl-14-hydroxy-7,8-dihydronormoprhine (EN 2260A), human metaolite (RF = 0.3), chicken
metabolite (RF = 0.3), and human metabolite (RF = 0.8)
The intensities of I 0 large peaks in each known spectrum were expressed as per cent of the base (largest) peak. Then
the intensity of the peak in the unknown corresponding to the base peak in the known was set eqal to I00% and the
other nine intensities recalculated to this new base peak for the unknown.
EN2260

RF = 0.3 (Human)

RF

=

0.3 (Chicken)

Naltrexone

R" = 0.8 (Human)

m/e

Intensity

m/e

Intensity

m/e

Intensity

m/e

Intensi ty

m/e

1ntensity

343
55
110
98
84
302
96
43
288
342

(100)
(56)
(33)
(24)
( 19)
( 17)
( 11)
(10)
(8)
(8)

343
55
110
98
84
302
96
43
288
342

( 100)
(94)
(39)
(32)
(28)
(24)
(18)
(79)
(8)
(8)

343
55
110
98
84
302
96
43
288
342

(100)
(84)
(45)
(36)
(22)
(20)
( 16)
(22)
( 10)
( 10)

341
55
31
29
110
300
84
40
256
98

( 100)
(55)
(36)
(33)
(18)
( 17)
( 16)
(15)
( 12)
( 12)

341
55
31
29
110
300
84
40
256
98

( 100)

.

( 122)
( 14)
( 102)
(23)
(20)
(100)

(52)
(9)
(51)

TABLE 2

Proton magnetic resonance spectra of various morphinans and metabolites ofnaltrexone isolated from human urine
and chicken liver enzyme preparation, and a metabolite of naloxone isolated from chicken urine
Spectra were run in CDCls solvent using tetramethylsilane as internal standard and a re reported in

~

values.

Morphinan or Metabolite

5P-H

6a-H

6P-H

EN 2260 (reduced naltrexone)
EN 2265 (reduced naloxone)
Human metabolite of naltrexone
Human metabolite of naltrexonea
Chicken metabolite of naltrexone
Chicken metabolite of naltrexone0
Chicken metabolite of naloxone
Dihydrohydroxycodeine C (iso configuration)b
Dihydrocodeineb
Dihydroisocodeineb

4.67
4.67
4.52
4.22
4.66
4.48
4.67
4.48
4.58
4.37

-

4.38 4. 16
4.40 4. 18
-

3.68- 3.38

-

c

-

-

4.40- 4.17
4.22 3.90
4.38 - 4.20

3.66 3.38

-

3.63 - 3.42

4.16 4.00
-

Solvent CDCla/C DsOD.
b Spectra obtained on a 60-mHz spectrometer with CDCJ 3 solvent by Dr. K. C. Rice, II I.
c 6a-H absorbances under H-OD.
a

corresponding chemical shift values for the 5{3 and
6{3 protons of the in vitro chicken metabolite of
naltrexone and the in vivo chicken metabolite of
naloxone. These data clearly show that these
compounds have the 6a-OH orientation. On the
other hand, using the same form of reasoning it is
clear that the naltrexone human metabolite should
have the 6~-0H orientation because of the chemical shift value of 4.52 of the 5{3-H doublet (J = 6
Hz) and the upfield shift of the 6a-H where
absorbances between 3.68 and 3.38 are observed.
These values would be similar to those expected of
compounds with 6,8-0H (6a-H) orientation.
Our assignment based on NMR considerations
supports the 6{3-0H orientation of the human

o

o

metabolite of naltrexone (2a) and the 6a-OH
orientation for the chicken metabolite. However, it
must be said that in both cases the presence of the
other epimer in amounts of 5% or less will go
undetected. The result on the human naltrexone
metabolite confirms the conclusion of Cone et a/.
(5). In addition, the present NMR analysis approach serves as a powerful basis for subsequent
investigations involving species differences in stereochemical enzyme action on related 6-keto compounds.
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